I am a pediatric endocrinologist specializing in the diagnosis and treatment of hormone disorders, including hypoglycemia, diabetes, thyroid disease, and growth and puberty disorders. I have a special interest in caring for children with hypoglycemia and am dedicated to helping families navigate both common and rare causes of low blood sugar.
I provide compassionate, family-centered care and value the relationships I build with my patients and their families. I listen to the needs of my patients and their caregivers and work with them to develop personalized treatment plans that support each child's health and well-being.
My research focuses on the genetic causes of diabetes and congenital hyperinsulinism, with the goal of understanding how disease-causing variants disrupt pancreatic beta cell development and function. My laboratory uses translational and basic science approaches, including patient-derived stem cell models, to uncover disease mechanisms and identify new therapeutic strategies. My research has been supported by the American Diabetes Association, the Pediatric Endocrine Society and the Orphan Disease Center.
When I'm not caring for patients or working in the lab, I enjoy spending time with my family and traveling.
BSc: Anatomy and Cell Biology, McGill University, Montreal, QC, 2006
MSc: Pathology, University of Western Ontario, ON, 2008
MD: St. Georges University, Grenada, West Indies, 2013
Pediatric Residency: East Carolina University, Greenville, NC, 2016
Fellowship: Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2020
Research Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2021
Hypoglycemia; hyperinsulinism; ketotic hypoglycemia
Disorders of beta cell function; monogenic diabetes; congenital hyperinsulinism
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Using Human Induced Pluripotent Stem Cell-Derived Organoids to Identify New Pathologies in Patients With PDX1 Mutations. Gastroenterology. 2022; 163(4):1053-1063.e7.
Functional human gastrointestinal organoids can be engineered from three primary germ layers derived separately from pluripotent stem cells. Cell Stem Cell. 2022; 29(1):36-51.e6.
Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. Journal of Biological Chemistry. 2010; 285(44):33623-33631.
Transcription factor expression in the developing human fetal endocrine pancreas. Diabetologia. 2008; 51(7):1169-1180.
c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic beta-cells in c-KitW-v mutant mice. Endocrinology. 2007; 148(11):5520-5530.
A worldwide perspective on clinical characteristics and treatment of youth with monogenic diabetes in the SWEET registry. Journal of the Endocrine Society. 2026; 10(4):bvag064.
Patient-derived induced pluripotent stem cells for precision modelling of monogenic beta cell disorders. Frontiers in Endocrinology. 2026; 17:1819394.
1670-P: Enteroendocrine Deficiencies in PDX1- and RFX6-MODY. Diabetes. 2025; 74(Supplement_1).
Genetic variants and characterization of MODY in a single, large pediatric referral center. Journal of Clinical & Translational Endocrinology. 2025; 40:100398.
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Research & Care. 2025; 13(2).
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey